US Stock MarketDetailed Quotes
ROIV Roivant Sciences
- 12.120
- -0.360-2.88%
Close Dec 3 16:00 ET
- 12.110
- -0.010-0.09%
Post 19:17 ET
8.82BMarket Cap2.08P/E (TTM)
12.460High11.950Low5.20MVolume12.300Open12.480Pre Close63.40MTurnover1.40%Turnover Ratio2.32P/E (Static)727.95MShares13.05552wk High1.71P/B4.51BFloat Cap9.68552wk Low--Dividend TTM371.75MShs Float16.760Historical High--Div YieldTTM4.09%Amplitude2.520Historical Low12.202Avg Price1Lot Size
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Roivant Sciences Stock Forum
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets.
Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
No comment yet